Search Results - "Dompe, Nicholas"

  • Showing 1 - 9 results of 9
Refine Results
  1. 1

    A CRISPR screen identifies MAPK7 as a target for combination with MEK inhibition in KRAS mutant NSCLC by Dompe, Nicholas, Klijn, Christiaan, Watson, Sara A, Leng, Katherine, Port, Jenna, Cuellar, Trinna, Watanabe, Colin, Haley, Benjamin, Neve, Richard, Evangelista, Marie, Stokoe, David

    Published in PloS one (18-06-2018)
    “…Mutant KRAS represents one of the most frequently observed oncogenes in NSCLC, yet no therapies are approved for tumors that express activated KRAS variants…”
    Get full text
    Journal Article
  2. 2
  3. 3
  4. 4

    whole-genome RNAi screen identifies an 8q22 gene cluster that inhibits death receptor-mediated apoptosis by Dompe, Nicholas, Rivers, Celina Sanchez, Li, Li, Cordes, Shaun, Schwickart, Martin, Punnoose, Elizabeth A, Amler, Lukas, Seshagiri, Somasekar, Tang, Jerry, Modrusan, Zora, Davis, David P

    “…Deregulation of apoptosis is a common occurrence in cancer, for which emerging oncology therapeutic agents designed to engage this pathway are undergoing…”
    Get full text
    Journal Article
  5. 5

    Abstract 4410: Predictive model of palbociclib response reveals indications in which CDK4/6 inhibitor can be a potential combination partner by Hafner, Marc, Dompe, Nicholas, Zhou, Wei, Lin, Eva, Durrbaum, Milena, Daemen, Anneleen, Junttila, Melissa R., Metcalfe, Ciara, Merrick, Karl

    Published in Cancer research (Chicago, Ill.) (01-07-2019)
    “…CDK4/6 inhibitors are a promising class of targeted therapies, with three molecules (palbociclib, ribociclib, and abemaciclib) approved for advanced…”
    Get full text
    Journal Article
  6. 6
  7. 7

    Abstract B22: Potential combinatorial strategies to overcome drug resistance in BRAF-mutant melanoma by Dompe, Nicholas A., Lin, Eva, Peng, Jing, Chan, Grace, Tien, Janet, Merchant, Mark, Bourgon, Richard, Settleman, Jeffrey, Wilson, Timothy, Neve, Richard M.

    Published in Clinical cancer research (15-02-2015)
    “…RAF and MEK inhibitors are used to target malignant melanomas harbouring BRAF V600E mutations, but resistance to these therapies remains a significant…”
    Get full text
    Journal Article
  8. 8
  9. 9

    Amphiregulin and PTEN evoke a multimodal mechanism of acquired resistance to PI3K inhibition by Edgar, Kyle A, Crocker, Lisa, Cheng, Eric, Wagle, Marie-Claire, Wongchenko, Matthew, Yan, Yibing, Wilson, Timothy R, Dompe, Nicholas, Neve, Richard M, Belvin, Marcia, Sampath, Deepak, Friedman, Lori S, Wallin, Jeffrey J

    Published in Genes & cancer (01-03-2014)
    “…Phosphoinositide-3 kinase (PI3K) signaling pathway alterations occur broadly in cancer and PI3K is a promising therapeutic target. Here, we investigated…”
    Get full text
    Journal Article